- Home
- RIME vs CERO Comparison
RIME vs CERO Comparison
Compare RIME & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIME
- CERO
- Stock Information
- Founded
- RIME 1982
- CERO 2017
- Country
- RIME United States
- CERO United States
- Employees
- RIME N/A
- CERO N/A
- Industry
- RIME
- CERO
- Sector
- RIME
- CERO
- Exchange
- RIME NYSE
- CERO Nasdaq
- Market Cap
- RIME 8.3M
- CERO 8.4M
- IPO Year
- RIME 1994
- CERO N/A
- Fundamental
- Price
- RIME $0.04
- CERO $2.34
- Analyst Decision
- RIME
- CERO
- Analyst Count
- RIME 0
- CERO 0
- Target Price
- RIME N/A
- CERO N/A
- AVG Volume (30 Days)
- RIME 114.8M
- CERO 80.5M
- Earning Date
- RIME 02-19-2025
- CERO 02-20-2025
- Dividend Yield
- RIME N/A
- CERO N/A
- EPS Growth
- RIME N/A
- CERO N/A
- EPS
- RIME N/A
- CERO N/A
- Revenue
- RIME $32,479,657.00
- CERO N/A
- Revenue This Year
- RIME N/A
- CERO N/A
- Revenue Next Year
- RIME N/A
- CERO N/A
- P/E Ratio
- RIME N/A
- CERO N/A
- Revenue Growth
- RIME 11.81
- CERO N/A
- 52 Week Low
- RIME $0.04
- CERO $2.22
- 52 Week High
- RIME $1.97
- CERO $1,280.00
- Technical
- Relative Strength Index (RSI)
- RIME N/A
- CERO 32.54
- Support Level
- RIME N/A
- CERO $2.83
- Resistance Level
- RIME N/A
- CERO $3.50
- Average True Range (ATR)
- RIME 0.00
- CERO 1.13
- MACD
- RIME 0.00
- CERO 0.05
- Stochastic Oscillator
- RIME 0.00
- CERO 1.43
About RIME ALGORHYTHM HOLDINGS INC
Algorhythm Holdings Inc is a holding company with two primary investments. It operates through its subsidiaries, one of which is an emerging leader in the AI-enabled global logistics industry. The other subsidiary is engaged in consumer karaoke products, Which designs and distributes the industry's widest assortment of at-home and in-car karaoke entertainment products.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.